1. Losano R., Naghavi M., Foreman K. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Diseases study. Lancet. 2012; 380 (9859): 2095-2118. https://doi.org/10.1016/S0140-6736(12)61728-0.
2. Sin D.D., Anthonisen N.R., Soriano J.B., Agusti F.G. Mortality in COPD: Role of comorbidities. Eur. Respir. J. 2006; 28 (6): 1245-1257. https://doi.org/10.1183/09031936.00133805.
3. Buch P., Friberg J., Scharling H. et al. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart study. Eur. Respir. J. 2003; 21 (6): 1012-1016. https://doi.org/10.1183/09031936.03.00051502.
4. Shibata Y., Watanabe T., Osaka D. et al. Impairment of pulmonary function is an independent risk factor for atrial fibrillation: the Takahata study. Int. J. Med. Sci. 2011; 8 (7): 514-522.
5. Stewart S., Hart C.L., Hole D.J. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart. 2001; 86 (5): 516-521. https://doi.org/10.1136/heart.86.5.516.
6. Li J., Agarwal S.K., Alonso A. et al. Airflow obstruction, lung function, and incidence of atrial fibrillation the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2014; 129 (9): 971-980. https://doi.org/10.1161/CIRCULATIONAHA.113.004050.
7. Yo C.H., Lee S.H., Chang S.S. et al. Value of high-sensitivity C-reactive protein assays in predicting atrial fibrillation recurrence: a systematic review and meta-analysis. Br. Med. J. Open. 2014; 4 (2): e004418. https://doi.org/10.1136/bmjopen-2013-004418.
8. Feary J.R., Rodrigues L.C., Smith C.J. et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010; 65 (11): 956-962. https://doi.org/10.1136/thx.2009.128082.
9. Nagorni-Obradovic L.M., Vukovic D.S. The prevalence of COPD co-morbidities in Serbia: results of a national survey. NPJ Prim. Care Respir. Med. 2014; 24: 140-148.
10. Truelsen T., Prescott E., Lange P. et al. Lung function and risk of fatal and non-fatal stroke. The Copenhagen City Heart study. Int. J. Epidemiol. 2001; 30 (1):145-151.
11. Andersson T., Magnuson A., Bryngelsson I.L. et al. All-cause mortality in 272 186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study. Eur. Heart J. 2013; 34 (14): 1061-1067. https://doi.org/10.1093/eurheartj/ehs469.
12. Waatevik M., Johannessen A., Real F.G. et al. Oxygen desaturation in 6-min walk test is a risk factor for adverse outcomes in COPD. 2016; 48 (1): 82-91. https://doi.org/10.1183/13993003.00975-2015.
13. Singh S.J., Puhan M.A., Andrianopoulos V. et al. An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease. Eur. Respir. J. 2014; 44 (6): 1447-1478. https://doi.org/10.1183/09031936.00150414.
14. Gökdeniz T., Kalaycıoğlu E., Boyacı F. et al. The BODE index, a multidimensional grading system, reflects impairment of right ventricle functions in patients with chronic obstructive pulmonary disease: a speckle-tracking study. Respiration. 2014; 88 (3): 223-233. https://doi.org/10.1159/000365222.
15. Aanerud M., Saure E.W., Benet M. et al. Serial Measurements of Arterial Oxygen Tension are Associated with Mortality in COPD. COPD. 2015; 12 (3): 287-294.
16. Sundh J., Jansen C., Lisspers K. et al. The Dyspnoea, Obstruction, Smoking, Exacerbation (DOSE) index is predictive of mortality in COPD. Prim. Care Respir. J. 2012; 21 (3): 295-301.
17. Ladeira I., Gomes T., Castro A. The overall impact of COPD (CAT) and BODE index on COPD male patients: correlation? Rev. Port. Pneumol. 2015; 21 (1): 11-15.
18. de Torres J.P., Casanova C., Marín J.M. et al. Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE. Thorax. 2014; 69 (9): 799-804. https://doi.org/10.1136/thoraxjnl-2014-205770.
19. Stolz D., Meyer A., Rakic J. et al. Mortality risk prediction in COPD by a prognostic biomarker panel. Eur. Respir. J. 2014; 44 (6): 1557-1570. https://doi.org/10.1183/09031936.00043814.
20. Белевский А.С., ред. Хроническая обструктивная болезнь легких. М.: Российское респираторное общество; 2016.
21. Kuang-Ming Liao, Chung-Yu Chen. Incidence and risk factors of atrial fibrillation in Asian COPD patients. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 2523-2530. https://doi.org/10.2147/COPD.S143691.
22. MacDonald M.I., Shafuddin E., King P.T. et al. Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. Lancet Respir. Med. 2016; 4 (2): 138-148.
23. Terzano C., Romani S., Conti V. et al. Atrial fibrillation in the acute, hypercapnic exacerbations of COPD. Eur. Rev. Med. Pharmacol. Sci. 2014; 18 (19): 2908-2917.
24. Vukic Dugac A., Ruzic A., Samarzija M. et al. Persistent endothelial dysfunction turns the frequent exacerbator COPD from respiratory disorder into a progressive pulmonary and systemic vascular disease. Med. Hypotheses. 2015; 84 (2): 155-158. https://doi.org/10.1016/j.mehy.2014.11.017.
25. Гельцер Б.И., Бродская Т.А., Невзорова В.А. Оценка артериальной ригидности у больных хронической обструктивной болезнью легких. Пульмонология. 2008; 1: 45-50.
26. Киняйкин М.Ф., Суханова Г.И., Удовиченко И.А. Роль гипоксемии в формировании миокардиальных повреждений и нарушений гемостаза у больных хронической обструктивной болезнью легких. Бюллетень физиологии и патологии дыхания. 2011; 41: 8-12.
27. Tükek T., Yildiz P., Atilgan D. et al. Effect of diurnal variability of heart rate on development of arrhythmia in patients with chronic obstructive pulmonary disease. Int. J. Cardiol. 2003; 88 (2): 199-206.
28. Павлова О.В., Кичигин В.А., Мадянов И.В. Содержание гормонов коры надпочечников в крови у больных хронической обструктивной болезнью легких. Здравоохранение Чувашии. 2012; 4 (32): 66-72.